A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, double-blind, randomized, multicenter, placebo-controlled, three arm
parallel study to evaluate the efficacy and safety of two different dosages (30 IU daily and
60 IU daily) of TNX-1900 in patients with chronic migraine.